Lynkuet: the newest hot flash drug, and the one whose price nobody publishes

What is Lynkuet?

Lynkuet is a prescription non-hormonal capsule for hot flashes: a neurokinin 1 (nk1) and neurokinin 3 (nk3) receptor antagonist approved by the FDA on October 24, 2025 under application 219469, with one labelled indication, the treatment of moderate to severe vasomotor symptoms due to menopause. It blocks the NK1 and the NK3 receptor in the brain's temperature-control signalling rather than replacing the estrogen that fell, and that second receptor is the whole difference between it and the drug that came before it. Lynkuet is the brand name and elinzanetant is the molecule inside it, and neither is a hormone, a bioidentical, or a compounded preparation.

No boxed warning is not the same thing as no warnings. The Lynkuet label carries 4 Warnings and Precautions, including one for seizure risk that the 08/2026 revision widened, and it still requires a liver panel before the first dose. Both non-hormonal drugs, side by side.

Two receptors, and a bedtime dose

Veozah blocks the neurokinin 3 receptor. Lynkuet blocks neurokinin 1 as well. That is the mechanistic claim in the class and it is the reason the drug exists as a separate product rather than a me-too. What the FDA-approved US label does with the extra receptor is nothing: the Clinical Studies section carries the same single vasomotor indication, measured the same way.

The dosing instruction is the practical difference you will feel first. 120 mg, taken as two 60 mg capsules, swallowed whole, once daily at bedtime. Veozah is taken once a day with or without food and no timing instruction. Lynkuet is a bedtime drug because of what section 5.1 of its label describes, and that is worth reading before you plan your first week on it.

No boxed warning, and the 4 warnings it does carry

Lynkuet has no boxed warning. The boxed warning field is absent from the openFDA label record for this drug entirely, which is a structured-data absence rather than a failure to find the text on a rendered page. That is a genuine advantage over Veozah, whose hepatotoxicity warning was boxed on December 16, 2024 after postmarketing liver injury. It also gets quoted as though it settles the safety question, and it does not.

What the 08/2026 revision did to the seizure warning, which is not what you have read elsewhere

The label's own Recent Major Changes field records Warnings and Precautions (5.4) at revision 08/2026, and that is all it records. It does not say the section is new, and it is not. Pages that tell you a seizure warning was added in August 2026 are reading a revision marker as an origin date.

The card above has the delta. It matters because of who the warning now covers. On the original label the caution was aimed at women with a seizure history. It is now aimed at everyone taking the drug, and the label tells prescribers to say so out loud. Approval was October 24, 2025, so anything written in the first months after launch describes the narrower version.

Check both yourself: the label as approved on October 24, 2025 against the prescribing information on DailyMed, recorded verbatim in the label's own Recent Major Changes field. DailyMed carries the current version only, which is why a comparison needs the as-approved PDF beside it.

The liver panel it still requires

Both drugs in this class start with the same blood test. ALT, AST, alkaline phosphatase, total bilirubin and direct bilirubin, before the first dose. Both use the same starting gate: Do not start if ALT or AST is at or above 2 times the upper limit of normal, or total bilirubin is at or above 2 times ULN.

4 fewer lab appointments in the first nine months is the most concrete thing this drug offers over its competitor, and it is worth real money and real hours. It does not make the drug monitoring-free, and any telehealth intake that gets you Lynkuet without ordering a baseline hepatic panel has skipped a step the label requires.

Who cannot take Lynkuet

• Pregnancy. The label states that exposure to LYNKUET may cause pregnancy loss or stillbirth.

That is a shorter contraindication list than Veozah's, which rules out known cirrhosis, severe renal impairment or end-stage renal disease, and any concomitant CYP1A2 inhibitor. The pregnancy contraindication on Lynkuet is worded severely on the label, and perimenopausal women are still capable of conceiving, which makes it less theoretical than it sounds for the younger half of this audience. Our perimenopause hub covers that window.

Section 5.1 is the one to think about if you drive, work nights, or operate anything. Nervous system effects were reported in 11.9% of women on drug against 3.5% on placebo across the three OASIS trials. In a driving-simulator study in 64 healthy women, mean standard deviation of lateral position did not cross the impairment threshold, and the label states that driving ability was impaired in some subjects after the initial dose.

What the trials showed, with the placebo column

Two 12-week trials sit in the label's Clinical Studies section, both reported in one paper covering 796 randomised women. The placebo column is shown beside the drug column on purpose: the placebo arms in these trials lost between five and seven hot flashes a day on their own, and a drug number quoted alone will mislead you about what the drug did.

Changes are least-squares means from baseline at week 12. Percentages: Calculated from the label's own baseline count and least-squares mean change. Neither the label nor the published trial reports a percentage. Both trials published as JAMA 2024 Aug 22;332(16):1343-1354 (PMID 39172446). The 52-week study, OASIS 3, is published as JAMA Internal Medicine 2025 Nov;185(11):1319-1327 (PMID 40920404).

What Lynkuet costs, and why we will not tell you

Bayer publishes no US list price for Lynkuet that is reachable from the open web. Bayer-controlled pages return HTTP 403 to automated clients and no government source carries a figure. Aggregators circulate a number. We are not printing it, because we could not confirm it against any source we could reach.

Set that beside the competitor. Astellas publishes Veozah's list price of $566 for a 30-day supply on a page anyone can open, with average out-of-pocket figures broken out by commercial insurance, Medicare Part D, Medicaid and uninsured. One company in this two-company class lets you find out what its drug costs before you sit in front of a prescriber. The other does not.

That distinction is the entire axis this site grades on. We score 16 hormone platforms A to F on what they disclose before intake, and 1 earns an A, because publishing every price where a shopper can read it without giving up an email address turns out to be rare. Applied to the drug makers, Astellas passes and Bayer fails. A price you cannot check in advance is a price you find out at the pharmacy counter.

European Medicines Agency: Authorised in the EU. CHMP positive opinion September 18, 2025, EU marketing authorisation November 17, 2025. The EU medicine record is public, and European price transparency rules differ from US ones, so a European figure would not tell a US reader what she will pay.

Where this sits against hormone therapy

The Menopause Society 2023 nonhormone therapy position statement says: Hormone therapy remains the most effective treatment for vasomotor symptoms and should be considered in menopausal women within 10 years of their final menstrual periods. Read the date on that document before you read anything into it. Accepted March 21, 2023, before Veozah was approved and more than two years before Lynkuet was. It recommends fezolinetant at Level I. Elinzanetant is named in its text as a drug then in development, and it carries no recommendation and no evidence level in the recommendations table, so nothing in it endorses Lynkuet.

So for a woman with no contraindication to estrogen, hormone therapy is the more effective route by the guideline's own reading, and it is cheaper on our verified numbers. Start with the scored provider rankings, estradiol by delivery form and price, or the price-sorted table.

For a woman who cannot take estrogen, this class is the FDA-approved route and it has two members. Veozah (fezolinetant) is the older one, with a published price and a heavier monitoring schedule. The head to head puts both labels in one table, and Veozah alternatives covers what is in the pipeline behind them.